Abstract
Among neuroendocrine carcinomas of the gut, well-differentiated tumors are highly vascularized, featuring specific characteristics on contrast-enhanced imaging. Well-differentiated neuroendocrine tumors spontaneously harbor hypervascular enhancement, coexisting with areas of necrosis mainly located at the center of tumor lesions. When exposed to vascular endothelial growth factor (VEGFR) inhibitors such as sunitinib, target lesions display few if any variation in tumor size, but rather detectable modifications in tumor density. In several patients treated with targeted therapy, a significant decrease of tumor density at first tumor evaluation can be detected as compared to baseline. Consistently, the two randomized trials leading to approval of sunitinib and everolimus in pancreatic neuroendocrine tumors report objective response rate below 10%, emphasizing that Response Evaluation Criteria in Solid Tumors (RECIST), that focus only on the largest diameters of target lesions, may be insufficient to capture the full benefit of targeted therapies. Alternative criteria, such as those developed by Choi et al., consider both the size and the density of the tumor as parameters for response evaluation. Choi criteria have been recently ...Continue Reading
References
Feb 3, 2000·Journal of the National Cancer Institute·P TherasseS G Gwyther
Apr 5, 2001·The New England Journal of Medicine·H JoensuuG D Demetri
Oct 11, 2001·Journal of Hepatology·J BruixUNKNOWN EASL Panel of Experts on HCC
Sep 29, 2004·Lancet·Jaap VerweijIan Judson
Nov 24, 2004·British Journal of Cancer·A CouvelardF Pezzella
Dec 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Clarisse DromainEric Baudin
Nov 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sandrine FaivreEric Raymond
Dec 6, 2005·Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]·M RodallecY Menu
Aug 16, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ghassan K Abou-AlfaLeonard B Saltz
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
May 2, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Haesun ChoiRobert S Benjamin
May 2, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert S BenjaminChuslip Charnsangavej
Aug 11, 2007·Nature Reviews. Drug Discovery·Sandrine FaivreEric Raymond
Feb 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles D BlankeErnest C Borden
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Jan 13, 2009·Cancer Treatment Reviews·I M E DesarW T A van der Graaf
May 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew X ZhuRakesh K Jain
Jul 10, 2009·The Lancet Oncology·Sandrine FaivreAnn Lii Cheng
Nov 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sandrine J FaivreEric Raymond
Feb 23, 2010·Seminars in Liver Disease·Riccardo Lencioni, Josep M Llovet
Nov 26, 2010·Endocrinology and Metabolism Clinics of North America·Sandrine FaivreEric Raymond
Feb 11, 2011·The New England Journal of Medicine·Eric RaymondPhilippe Ruszniewski
Feb 11, 2011·The New England Journal of Medicine·James C YaoUNKNOWN RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group
May 3, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sandrine FaivreEric Raymond
Citations
Oct 23, 2012·Cancer Metastasis Reviews·Cindy NeuzilletEric Raymond
Aug 25, 2012·Targeted Oncology·Eric RaymondSandrine Faivre
Mar 15, 2016·Best Practice & Research. Clinical Endocrinology & Metabolism·Tobias BaumannDamian Wild
Nov 1, 2013·Drug Discovery Today·Federica BarbieriTullio Florio
Oct 5, 2015·Cancer Metastasis Reviews·Rocio Garcia-CarboneroUNKNOWN Spanish Cooperative Group of Neuroendocrine Tumors (GETNE)
May 8, 2015·European Journal of Nuclear Medicine and Molecular Imaging·L BodeiI Drozdov
Jul 15, 2016·Future Oncology·Nicola FlaumMairéad G McNamara
Dec 20, 2013·Endocrine-related Cancer·Louis de MestierGuillaume Cadiot
Sep 5, 2013·Therapeutic Advances in Gastroenterology·Aaron I Vinik, Eric Raymond
Jul 13, 2014·Endocrine-related Cancer·Irvin M ModlinMark Kidd
May 17, 2018·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·X Merino-CasabielJ Capdevila
Nov 22, 2017·British Journal of Cancer·Angela LamarcaJuan W Valle
Dec 21, 2012·Oncology Reports·Zhiyun CaoJian Du
Nov 12, 2014·Molecular Medicine Reports·Lian Tao LiJun Nian Zheng
Sep 4, 2019·British Journal of Cancer·Mª Pilar Solis-HernandezPaula Jimenez-Fonseca
Mar 29, 2020·Cancers·Alberto SignorePaolo Marchetti
Apr 26, 2014·Endocrinology·Svenja NöltingKarel Pacak
Apr 2, 2020·Investigative Radiology·Alexandre HelbertJean-Marc Hyvelin
Feb 25, 2017·BMC Cancer·Yanji LuoShi-Ting Feng
Jun 22, 2017·Targeted Oncology·Diana MartinsUNKNOWN IEO ENETS Center of Excellence for GEP NETs
Dec 19, 2018·Drugs·Aura D Herrera-MartínezRichard A Feelders
Feb 8, 2020·Current Medicinal Chemistry·Jorge Barriuso, Angela Lamarca
Dec 17, 2019·Advances in Medical Sciences·Anna MalczewskaIrvin M Modlin
Apr 20, 2021·Reviews in Endocrine & Metabolic Disorders·Marie-Pierre VulliermeLouis de Mestier
Oct 26, 2021·Journal of Neuroendocrinology·Clarisse DromainAnders Sundin